200 related articles for article (PubMed ID: 31554191)
1. Computer-Aided Discovery of Small Molecule Inhibitors of Thymocyte Selection-Associated High Mobility Group Box Protein (TOX) as Potential Therapeutics for Cutaneous T-Cell Lymphomas.
Agrawal V; Su M; Huang Y; Hsing M; Cherkasov A; Zhou Y
Molecules; 2019 Sep; 24(19):. PubMed ID: 31554191
[TBL] [Abstract][Full Text] [Related]
2. High-mobility group box (TOX) antibody a useful tool for the identification of B and T cell subpopulations.
Maestre L; García-García JF; Jiménez S; Reyes-García AI; García-González Á; Montes-Moreno S; Arribas AJ; González-García P; Caleiras E; Banham AH; Piris MÁ; Roncador G
PLoS One; 2020; 15(2):e0229743. PubMed ID: 32106280
[TBL] [Abstract][Full Text] [Related]
3. Molecular profiling of TOX-deficient neoplastic cells in cutaneous T cell lymphoma.
Xu J; Huang H; Wang S; Chen Y; Yin X; Zhang X; Zhang Y
Arch Dermatol Res; 2020 Sep; 312(7):513-525. PubMed ID: 31676945
[TBL] [Abstract][Full Text] [Related]
4. TOX expression and role in CTCL.
McGirt LY; Degesys CA; Johnson VE; Zic JA; Zwerner JP; Eischen CM
J Eur Acad Dermatol Venereol; 2016 Sep; 30(9):1497-502. PubMed ID: 27345620
[TBL] [Abstract][Full Text] [Related]
5. TOX expression in cutaneous T-cell lymphomas: an adjunctive diagnostic marker that is not tumour specific and not restricted to the CD4(+) CD8(-) phenotype.
Schrader AM; Jansen PM; Willemze R
Br J Dermatol; 2016 Aug; 175(2):382-6. PubMed ID: 26931394
[TBL] [Abstract][Full Text] [Related]
6. TOX expression in cutaneous B-cell lymphomas.
Schrader AM; Jansen PM; Willemze R
Arch Dermatol Res; 2016 Aug; 308(6):423-7. PubMed ID: 27180090
[TBL] [Abstract][Full Text] [Related]
7. Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer.
Carabet LA; Lallous N; Leblanc E; Ban F; Morin H; Lawn S; Ghaidi F; Lee J; Mills IG; Gleave ME; Rennie PS; Cherkasov A
Eur J Med Chem; 2018 Dec; 160():108-119. PubMed ID: 30326371
[TBL] [Abstract][Full Text] [Related]
8. Discovery of selective dengue virus inhibitors using combination of molecular fingerprint-based virtual screening protocols, structure-based pharmacophore model development, molecular dynamics simulations and in vitro studies.
Mirza SB; Lee RCH; Chu JJH; Salmas RE; Mavromoustakos T; Durdagi S
J Mol Graph Model; 2018 Jan; 79():88-102. PubMed ID: 29156382
[TBL] [Abstract][Full Text] [Related]
9. TOX expression in different subtypes of cutaneous lymphoma.
Morimura S; Sugaya M; Suga H; Miyagaki T; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
Arch Dermatol Res; 2014 Nov; 306(9):843-9. PubMed ID: 25216799
[TBL] [Abstract][Full Text] [Related]
10. In silico identification of inhibitors targeting N-Terminal domain of human Replication Protein A.
Çınaroğlu SS; Timuçin E
J Mol Graph Model; 2019 Jan; 86():149-159. PubMed ID: 30366191
[TBL] [Abstract][Full Text] [Related]
11. Focused Library Generator: case of Mdmx inhibitors.
Xia Z; Karpov P; Popowicz G; Tetko IV
J Comput Aided Mol Des; 2020 Jul; 34(7):769-782. PubMed ID: 31677002
[TBL] [Abstract][Full Text] [Related]
12. Abelson tyrosine-protein kinase 1 as principal target for drug discovery against leukemias. Role of the current computer-aided drug design methodologies.
Speck-Planche A; Luan F; Cordeiro MN
Curr Top Med Chem; 2012; 12(24):2745-62. PubMed ID: 23368101
[TBL] [Abstract][Full Text] [Related]
13. Overview on the current status of virtual high-throughput screening and combinatorial chemistry approaches in multi-target anticancer drug discovery; Part I.
Geromichalos GD; Alifieris CE; Geromichalou EG; Trafalis DT
J BUON; 2016; 21(4):764-779. PubMed ID: 27685895
[TBL] [Abstract][Full Text] [Related]
14. Computational Approaches for the Discovery of Human Proteasome Inhibitors: An Overview.
Guedes RA; Serra P; Salvador JA; Guedes RC
Molecules; 2016 Jul; 21(7):. PubMed ID: 27438821
[TBL] [Abstract][Full Text] [Related]
15. Molecular docking studies of Traditional Chinese Medicinal compounds against known protein targets to treat non-small cell lung carcinomas.
Zhao GF; Huang ZA; Du XK; Yang ML; Huang DD; Zhang S
Mol Med Rep; 2016 Aug; 14(2):1132-8. PubMed ID: 27279494
[TBL] [Abstract][Full Text] [Related]
16. miRNA‑135a regulates Hut78 cell proliferation via the GATA‑3/TOX signaling pathway.
Wei H; Liu R; Guo X; Zhou Y; Sun B; Wang J
Mol Med Rep; 2019 Mar; 19(3):2361-2367. PubMed ID: 30747224
[TBL] [Abstract][Full Text] [Related]
17. Identification of novel PI3Kδ inhibitors by docking, ADMET prediction and molecular dynamics simulations.
Liu YY; Feng XY; Jia WQ; Jing Z; Xu WR; Cheng XC
Comput Biol Chem; 2019 Feb; 78():190-204. PubMed ID: 30557817
[TBL] [Abstract][Full Text] [Related]
18. Documenting and harnessing the biological potential of molecules in Distributed Drug Discovery (D3) virtual catalogs.
Abraham MM; Denton RE; Harper RW; Scott WL; O'Donnell MJ; Durrant JD
Chem Biol Drug Des; 2017 Nov; 90(5):909-918. PubMed ID: 28453915
[TBL] [Abstract][Full Text] [Related]
19. In-silico identification of inhibitors against mutated BCR-ABL protein of chronic myeloid leukemia: a virtual screening and molecular dynamics simulation study.
Kumar H; Raj U; Gupta S; Varadwaj PK
J Biomol Struct Dyn; 2016 Oct; 34(10):2171-83. PubMed ID: 26479578
[TBL] [Abstract][Full Text] [Related]
20. Structure-Based Virtual Screening.
Li Q; Shah S
Methods Mol Biol; 2017; 1558():111-124. PubMed ID: 28150235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
